Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

The company reported a patient death following treatment with Elevidys, having suffered acute liver failure.

Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.

On Wednesday, Sarepta and Roche Holdings AG (OTC:RHHBY) temporarily halted several clinical studies.

Also Read: Sarepta Therapeutics’ Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years

Roche, the company to which the treatment is licensed outside the US, has said that this was at the European Medicines Agency’s (EMA) request.

The companies have a therapeutic ...

https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death